A Single-Center Retrospective Evaluation of the Use of Oral Factor Xa Inhibitors in Patients With Cerebral Venous Thrombosis.

Marissa Z PowellKathryn Tremolet de VillersKerry A SchwarzDavid CaseToby Trujillo

Published in: The Annals of pharmacotherapy (2020)

Although the sample size is limited, these findings indicate that oral factor Xa inhibitors are a reasonable treatment option for patients with CVT. There was a trend toward more persistent symptoms in patients on warfarin, suggesting a potential improvement in recovery among patients that received an oral factor Xa inhibitor.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
atrial fibrillation
subarachnoid hemorrhage
prognostic factors
patient reported outcomes
risk assessment
depressive symptoms
human health
patient reported
replacement therapy